The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promotors and gut peptides.
Sikiric. P P; Seiwerth. S S; Grabarevic. Z Z; Petek. M M; Rucman. R R; Turkovic. B B; Rotkvic. I I; Jagic. V V; Duvnjak. M M; Mise. S S
Key Findings
- BPC‑157 given by injection or orally prevented ulcers in three different rat models (restraint stress, cysteamine, 96% ethanol).
- Standard ulcer medications (bromocriptine, amantadine, famotidine, cimetidine, somatostatin) did not protect against stress‑induced ulcers.
- Partial protection was seen with glucagon, NPY, and secretin, but not with CCK‑derived peptide.
- The protective effect appears linked to strong endothelial (blood‑vessel) protection.
Practical Outcomes
- The study suggests BPC‑157 may be a powerful gut‑protective agent, potentially useful for healing ulcers or stress‑related gut damage. However, the evidence is limited to animal models, so human dosing and safety are still unknown. Biohackers should treat this as promising pre‑clinical data and wait for human trials before adopting it as a routine protocol.
Summary
In rats, a 15‑amino‑acid peptide called BPC‑157 protected the stomach and duodenum from damage caused by stress, a chemical (cysteamine), and strong alcohol. It worked better than several common ulcer drugs and seemed to protect blood vessels in the gut.
Abstract
The protection of stomach and duodenum in conjecture with anti-inflammatory effect was demonstrated for a novel 15 amino acid peptide, coded BPC 157, a fragment of the recently discovered gastric juice peptide BPC. BPC 157 (i.p./i.g.) was investigated in rats in comparison with several reference standards in three experimental ulcer models (48 h-restraint stress, subcutaneous cysteamine, intragastrical 96% ethanol ulcer tests) (pre-/co-/post-treatment). Only BPC 157 regimens were consistently effective in all of the tested models. On the other hand, bromocriptine, amantadine, famotidine, cimetidine and somatostatin were ineffective (restraint stress). A dose-dependent protection (cysteamine) and/or partial positive effect (related to treatment conditions) (ethanol), was obtained with glucagon, NPY and secretin whereas CCK/26-30/was not effective. Based on Monastral blue studies BPC 157 beneficial effect appears to be related to a strong endothelial protection.
Study Information
pubmed
1994
10.1016/0024-3205(94)00796-9
101
9